PurpleDaisy Logo
PurpleDaisyResources
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog
Download on the App Store
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog

Biomarker Encyclopedia

500+ Items
Master Catalogs
  • All 500+ Biomarkers Directory
  • Longevity Reference MatrixPDF
Categories (500+ Markers)
  • Cardiovascular & Lipidology
  • Metabolic & Glycemic Control
  • Renal Physiology & Electrolytes
  • Hepatic & Biliary Function
  • Hematology & CBC
  • Iron Metabolism & Oxygen Transport
  • Endocrinology & Hormones
  • Micronutrients & Vitamins
  • Immunology & Longevity Clocks
Download Meridian on the App Store
Home/Biomarkers/Cardiovascular & Lipidology/Lp(a)
Cardiovascular & LipidologyAtherothrombosis & Valvular Biology

Lipoprotein(a) (Lp(a))

Lipoprotein(a) consists of an LDL-like particle covalently bound to apolipoprotein(a). Concentrations are over 90% genetically determined by the LPA locus, conferring independent causal risk for myocardial infarction, ischemic stroke, and calcific aortic valve stenosis.

Standard Range< 30 mg/dL (< 75 nmol/L)
Optimal Longevity< 14 mg/dL (< 30 nmol/L)
Measurement Unitnmol/L
Organ SystemAtherothrombosis & Valvular Biology
Routine Panels:Cardiovascular Risk AssessmentCardio IQ®Specialty Lipid Panel

Standard vs. Optimal Reference Rangesnmol/L

Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.

Interactive Range Analyzer
Unit: nmol/L
nmol/L
Presets:
0 nmol/LOptimal Zone Target41 nmol/L
Optimal Longevity Zone(7 nmol/L)

Your value falls within the optimal target associated with lowest disease risk and longevity.

Standard Reference Interval

< 30 mg/dL (< 75 nmol/L)

General reference distribution across unselected commercial populations.

Optimal Longevity Target

< 14 mg/dL (< 30 nmol/L)

Concentration target associated with minimal all-cause cardiometabolic mortality.

Molecular Mechanism & Clinical Purpose

Apolipoprotein(a) possesses structural homology with plasminogen, containing multiple kringle IV repeats. This molecular mimicry competitively inhibits tissue plasminogen activator-mediated fibrinolysis while delivering oxidized phospholipids directly to vascular endothelium, promoting both thrombosis and vascular calcification.

Differential Diagnosis

Elevated Levels (Lp(a) High)

  • •Genetically determined LPA gene variants
  • •End-stage renal disease / Nephrotic syndrome
  • •Severe postmenopausal estrogen withdrawal

Low Levels (Lp(a) Low)

  • •Genetically determined high kringle IV copy number
  • •Severe hepatic failure

Technical Reference & Deep Dive

Biochemistry & Enzymatic Pathways
At the cellular and molecular level, Lipoprotein(a) (Lp(a)) is central to lipoprotein particle assembly, apolipoprotein-receptor interactions, and subendothelial retention kinetics. Synthesis occurs primarily within hepatocytes and enterocytes, regulated by transcriptional co-activators (such as SREBP-2 and PPAR-alpha) and microsomal triglyceride transfer protein (MTP). Particle clearance is mediated through high-affinity endocytic receptors (including LDLR, LRP1, and scavenger receptors SR-B1). Circulating plasma half-life ranges from 2 to 4 days. Transcytosis across vascular endothelial cell monolayers occurs via scavenger receptor class B type 1 (SR-B1) and activin-like kinase 1 (ALK1), trapping particles within the subendothelial proteoglycan matrix where oxidative modification initiates foam cell formation.
Longevity Risk Architecture & Epidemiology
Elevated Lp(a) represents an independent cardiovascular hazard that remains unaffected by diet, lifestyle, or standard statin regimens. Lifelong genetic elevations accelerate arterial biological aging through unmitigated intimal oxidized phospholipid deposition.
Pre-Analytical Caveats & Diagnostic Workup

Pre-Analytical Considerations:

Standard testing requires a 10 to 12 hour overnight fast to minimize postprandial chylomicron interference, although Lp(a) direct immunoassay is less sensitive to prandial state than calculated LDL-C. Avoid strenuous high-intensity exercise 24 hours prior to blood draw. Serum separator tubes (SST) or EDTA plasma should be centrifuged within 2 hours. High-dose biotin (>5 mg/day) supplementation may interfere with competitive streptavidin-biotin immunoassays, requiring a 48-hour washout period.

Reflexive Testing Protocol:

  • Advanced Lipoprotein Particle Quantification (NMR spectroscopy or ion mobility LDL-P)
  • Lipoprotein(a) [Lp(a)] baseline evaluation for genetic cardiovascular risk stratification
  • Coronary Artery Calcium (CAC) score via non-contrast cardiac CT to evaluate calcified plaque burden
  • High-sensitivity C-Reactive Protein (hs-CRP) to assess systemic vascular inflammatory tone
  • Carotid intima-media thickness (CIMT) duplex ultrasound to assess subclinical atherosclerosis
Clinical Citations & Primary Literature (1)
  • [1]Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis - Lancet (2022). doi:10.1016/S0140-6736(22)01077-8
Common Panels:Cardiovascular Risk AssessmentCardio IQ®Specialty Lipid Panel
View All Panels

Associated Longevity Guides & Clinical Calculators

Medicine 3.0

Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Lipoprotein(a) (Lp(a)) into overall healthspan optimization.

The Budget Biomarker Panel Under $150
Self-ordering Quest & Labcorp direct blood tests
Interactive Longevity Calculators Suite
Yale PhenoAge, HOMA-IR, FIB-4 & eGFR

Related Cardiovascular & Lipidology Biomarkers

Apolipoprotein B
ApoB · < 60 mg/dL (or < 50 mg/dL in high-risk phenotypes)
Low-Density Lipoprotein Cholesterol
LDL-C · < 70 mg/dL (or < 55 mg/dL in secondary prevention)
High-Sensitivity C-Reactive Protein
hs-CRP · < 0.5 mg/L
PreviousApolipoprotein B (ApoB)Cardiovascular & LipidologyNextLow-Density Lipoprotein Cholesterol (LDL-C)Cardiovascular & Lipidology